Inventiva (IVA) Price & Analysis

Compare

7 Followers

IVA Stock Chart & Stats

Day’s Range― - ―

52-Week Range€1.43 - €4.67

Previous CloseN/A

Volume1.84K

Average Volume (3M)143.62K

Market Cap

€566.33M

Enterprise Value€95.51M

Total Cash (Recent Filing)€96.56M

Total Debt (Recent Filing)€54.33M

Price to Earnings (P/E)―

Beta0.97

Next Earnings

Sep 25, 2025

EPS Estimate

-0.55

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.68

Shares Outstanding139,151,280

10 Day Avg. Volume264,092

30 Day Avg. Volume143,622

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€6.25

Price Target Upside34.99% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Drug DevelopmentEnrollment for the Ph3 NATIV3 MASH trial is complete with a significant number of patients, indicating progress towards potential drug approval.

Financial StabilityCash reserves and additional financing provide an operational runway until the third quarter of 2026, ensuring financial stability for ongoing projects.

Regulatory SupportThe company has received authorization to implement its pipeline prioritization plan, demonstrating regulatory support for its strategic decisions.

Bears Say

Financial PerformanceIVA reported FY24 net loss of €184M.

Operational ChangesInventiva has conducted a 50% reduction in force and paused all preclinical research due to prioritization of the lanifibranor MASH program.

Strategic RisksA 50% reduction in workforce and pausing of all preclinical research reflects a strategic shift and potential risks due to narrowed focus.

Inventiva News

Inventiva initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Inventiva (IVA) with an Overweight rating and $26 price target The company is...

2d ago

IVA

Inventiva’s Strategic Positioning and Promising Developments Drive Buy Rating

Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Inventiva, retaining the price target of $20.00....

15d ago

IVA

Inventiva’s Strong Financial Position and Promising Phase 3 Trial Drive Buy Rating

Inventiva, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Ritu Baral from TD...

29d ago

IVA

Inventiva CMO Michael Cooreman to depart, Jason Campagna to succeed

Inventiva (IVA) announced a leadership transition with the appointment of Jason Campagna as president of research and development...

2M ago

IVA

Inventiva receives $10M milestone payment from Chia Tai-Tianqing Pharmaceutical

Inventiva (IVA) announced the receipt of a $10M milestone payment from Chia Tai-Tianqing Pharmaceutical Group, a subsidiary of...

2M ago

IVA

Inventiva’s Lanifibranor: A Promising Investment in the MASH Space with Strong Phase III Progress and Financial Backing

Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Inventiva (IVA – Research Report) and keeping...

3M ago

IVA

Inventiva describes share repurchase covered by Kepler Chevreux agreement

Pursuant to Article 241-2 of the AMF General Regulations, the purpose of this description is to present the...

3M ago

IVA

Inventiva’s Strategic Milestones and Promising Outlook Drive Buy Rating

Guggenheim analyst Seamus Fernandez has reiterated their bullish stance on IVA stock, giving a Buy rating yesterday. Seamus...

5M ago

IVA

Inventiva price target lowered to $9 from $12 at Guggenheim

Guggenheim analyst Etzer Darout lowered the firm’s price target on Inventiva (IVA) to $9 from $12 and keeps...

5M ago

IVA

Inventiva achieves milestone with Phase 3 study enrollment, says H.C. Wainwright

H.C. Wainwright analyst Ed Arce affirms a Buy rating on shares of Inventiva (IVA) after the company announced...

5M ago

IVA

Inventiva’s Strategic Advancements and Financial Strength Bolster Buy Rating

Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Inventiva (IVA – Research Report), retaining the...

5M ago

IVA

Inventiva’s Strategic Advancements and Financial Positioning Drive Buy Rating

Ritu Baral, an analyst from TD Cowen, maintained the Buy rating on Inventiva (0RNK – Research Report). The...

5M ago

IVA

Inventiva’s Promising Future: Buy Rating Backed by Phase III Milestone and Financial Stability

LifeSci Capital analyst Rami Katkhuda has maintained their bullish stance on IVA stock, giving a Buy rating yesterday....

5M ago

IVA

Inventiva SA Earnings Call: Positive Outlook Amid Challenges

Inventiva SA (($FR:IVA)) has held its Q4 earnings call. Read on for the main highlights of the call....

5M ago

IVA FAQ

What was Inventiva SA’s price range in the past 12 months?

Inventiva SA lowest stock price was €1.43 and its highest was €4.67 in the past 12 months.

What is Inventiva SA’s market cap?

Inventiva SA’s market cap is €566.33M.

When is Inventiva SA’s upcoming earnings report date?

Inventiva SA’s upcoming earnings report date is Sep 25, 2025 which is in 27 days.

How were Inventiva SA’s earnings last quarter?

Inventiva SA released its earnings results on Mar 26, 2025. The company reported -€1.68 earnings per share for the quarter, missing the consensus estimate of -€0.539 by -€1.141.

Is Inventiva SA overvalued?

According to Wall Street analysts Inventiva SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Inventiva SA pay dividends?

Inventiva SA does not currently pay dividends.

What is Inventiva SA’s EPS estimate?

Inventiva SA’s EPS estimate is -0.55.

How many shares outstanding does Inventiva SA have?

Inventiva SA has 139,151,280 shares outstanding.

What happened to Inventiva SA’s price movement after its last earnings report?

Inventiva SA reported an EPS of -€1.68 in its last earnings report, missing expectations of -€0.539. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Inventiva SA?

Currently, no hedge funds are holding shares in FR:IVA

Company Description

Inventiva SA

Inventiva (IVA) is a biopharmaceutical company focused on the development of innovative therapies to address unmet medical needs in the fields of metabolic diseases and fibrosis. The company leverages its proprietary drug discovery platform to create novel small molecules and is actively involved in the research and clinical development of treatments aimed at improving the quality of life for patients suffering from chronic conditions. Inventiva's core products include candidates targeting diseases such as non-alcoholic steatohepatitis (NASH) and other fibrotic disorders.

Inventiva (IVA) Earnings & Revenues

Historic Earnings Reports

IVA Stock 12 Month Forecast

Average Price Target

€6.25

▲(34.99% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","12":"€12","3.75":"€3.75","6.5":"€6.5","9.25":"€9.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€6.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.75,6.5,9.25,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2022","6":"Nov<br/>2022","9":"Jan<br/>2024","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.59,3.16,3.73,4.3,4.87,5.44,6.01,6.58,7.15,7.720000000000001,8.290000000000001,8.86,9.43,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.59,2.8715384615384614,3.153076923076923,3.434615384615385,3.716153846153846,3.997692307692308,4.27923076923077,4.560769230769231,4.842307692307692,5.123846153846154,5.405384615384616,5.686923076923077,5.968461538461539,{"y":6.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.59,2.583076923076923,2.5761538461538462,2.569230769230769,2.562307692307692,2.5553846153846154,2.5484615384615386,2.5415384615384613,2.5346153846153845,2.5276923076923077,2.520769230769231,2.5138461538461536,2.506923076923077,{"y":2.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.36,"date":1614556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.36,"date":1619827200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1630454400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.1,"date":1646092800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.39,"date":1651363200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.39,"date":1661990400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1667260800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.514,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.875,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.165,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.165,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >